Levodopa …

K K Jain MD†

Neuropharmacology & Neurotherapeutics

Updated 04.03.2021
Released 12.18.1998
Expires For CME 04.03.2024

Levodopa

Author: K K Jain MD†

See Contributor Disclosures

Levodopa

In This Article

Quick Link

Introduction

Overview

Since its introduction into clinical use for Parkinson disease more than half a century ago, levodopa, a precursor of dopamine, remains the gold standard. It is used in combination with carbidopa, and various preparations are being developed to enhance its bioavailability as well as improve its delivery for reducing complications due to plasma level fluctuations. This article reviews the pharmacology, clinical trials, and adverse effects of levodopa. Several movement disorders can occur as adverse effects of levodopa therapy, eg, choreoathetosis, dystonia, akathisia, myoclonus, tremor, and dyskinesias.

Key points

	• Levodopa is a precursor for dopamine, and its anti–Parkinson disease effects are mediated by the synthesis of dopamine, which subsequently interacts with dopamine receptors.
	• More than half a century after its introduction into clinical use, levodopa remains the gold standard for the treatment of Parkinson disease.
	• To overcome the short half-life of levodopa, it is usually combined with the decarboxylase inhibitor, carbidopa, and various preparations are being developed to enhance its bioavailability as well as improve its delivery for reducing complications due to plasma level fluctuations.
	• Several movement disorders can occur as adverse effects of levodopa therapy, eg, choreoathetosis, dystonia, akathisia, myoclonus, tremor, and dyskinesias.
	• Levodopa-induced dyskinesias are problematic, and to prevent peak dose dyskinesias, levodopa concentrations should be steadily maintained in the therapeutic range.

Historical note and terminology

Levodopa was demonstrated in nature, and a simplified manufacturing process was described in 1913 (16). Experimental studies in the 1950s showed that levodopa could reverse reserpine-induced akinesia in rabbits, but the biochemical basis of this action was not clear until Carlsson demonstrated that dopamine in the brain was depleted with reserpine and could be restored with levodopa (07). In 1961 Birkmayer and Hornykiewicz showed that intravenous dopa briefly improved symptoms in patients with Parkinson disease (03). Seven years later, Cotzias showed the effectiveness of levodopa for Parkinson disease by clinical trial (10). Since its introduction into the clinical use in the early 1970s, levodopa remains the single most effective treatment for Parkinson disease. Stable and controlled formulations that ensure clinical response need to be developed to reduce the undesirable effects that restrict its efficacy (40). More than half a century after its introduction into clinical practice, levodopa remains the gold standard for treatment of Parkinson disease.

Pharmacology

Pharmacokinetics. Levodopa is a precursor for dopamine and is actively transported across the intestinal wall and the blood-brain barrier by a branched chain amino acid carrier. This is important because dopamine itself cannot cross the blood-brain barrier. It is taken up by the dopaminergic neurons and decarboxylated in the presynaptic terminal to form dopamine; this then replaces the dopamine lost in the degeneration of substantia nigra pars compacta. The major urinary metabolite of levodopa in humans appears to be dopamine and homovanillic acid. In a 24-hour urine specimen, homovanillic acid accounts for 13% to 42% of the ingested dose of levodopa. Because of the short plasma half-life of levodopa, there are marked fluctuations in plasma drug concentration, which may lead to fluctuations in the therapeutic response. Strategies to optimize levodopa pharmacokinetics include liquid preparations, controlled release formulations, and the use of inhibitors of levodopa metabolism (09). However, these efforts have been only partly successful so far.

Pharmacodynamics. It is generally recognized that the antiparkinsonian effects of levodopa are mediated by the synthesis of dopamine and its subsequent interaction with dopamine receptors. This concept is supported by clinical and experimental observations that dopamine receptor antagonist drugs block the antiparkinsonian effect of levodopa.

Pharmacokinetics of levodopa explains some of the problems that arise during chronic therapy, which may be due to irregular uptake variations in plasma concentrations, and new approaches to delivery and uptake of levodopa are likely to improve its anti-parkinsonian effect (23). Pharmacokinetic-pharmacodynamic modeling has been used to study the concentration effect relationship of levodopa in patients with Parkinson disease. The findings support the concept that reduced dopamine storage in the striatum is responsible for the occurrence of response fluctuations. There is some evidence that the reduced efficacy of the controlled release preparations, (formerly considered to be due lower bioavailability alone) also has a pharmacodynamic basis. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion has shown that in an unmedicated subject, it takes approximately 51.4 minutes until the peak levodopa effect is reached after a bolus dose (54).

Preparations of levodopa. Levodopa is available as immediate-release tablets, disintegrating tablets, controlled-release tablets, and extended-release capsules. Levodopa is so extensively metabolized in the periphery that only 1% of the ingested drug reaches the central nervous system. To overcome this, levodopa is often combined with a decarboxylase inhibitor. The most used of these decarboxylase inhibitors is carbidopa combined with levodopa. In most countries outside the United States, levodopa is sold in combination with a peripheral decarboxylase inhibitor benserazide. A controlled release version of this is also available.

Efficacy of levodopa is significantly reduced due to metabolism, subsequent low bioavailability, and irregular fluctuations in its plasma levels. Considerable progress has been made to improve the delivery of levodopa to enhance its bioavailability and reduce plasma fluctuations as well as motor complications experienced by patients that can result from pulsatile stimulation of the striatal dopamine receptors (33). Products under development or recently released include intestinal infusion, sustained-release microtablets, gastric-retentive formulations, and methods for delivery of the drug by inhalation or subcutaneous infusion (24). Transdermal levodopa micropumps are also being investigated for efficacy (41).

Sustained/extended release preparations. Controlled studies have shown that immediate release and sustained release levodopa and carbidopa both maintain a similar level of control in Parkinson disease after 5 years, as compared with baseline.

IPX066 (levodopa and carbidopa), an extended-release carbidopa-levodopa formulation, is rapidly absorbed with onset of benefit like the immediate-release preparation, but it provides more sustained therapeutic levodopa levels and longer duration of clinical benefit. In various studies, levodopa and carbidopa improved symptoms in patients with both early and advanced Parkinson disease and led to significantly improved Unified Parkinson Disease Rating Scale scores and ON times, without troublesome dyskinesias as compared to other levodopa formulations (11). Phase 3 studies of IPX066 in patients with Parkinson disease have shown a significant reduction in OFF time compared with immediate-release carbidopa-levodopa and carbidopa-levodopa-entacapone; it is approved in the United States as Rytary and in the European Union as Numient (30).

Gel formulations for gastrointestinal administration. Intrajejunal infusion of a gel formulation of L-dopa/carbidopa is in clinical use in Europe, and its efficacy in controlling motor fluctuations has been shown in a randomized, controlled trial.

A systematic review of the various studies has shown that levodopa-carbidopa intestinal gel reduces OFF time, increases ON time without increasing troublesome dyskinesias, and improves quality of life in patients with Parkinson disease, but data evaluating long-term efficacy as well as safety are still limited (55). It is a useful treatment option in patients with severe motor fluctuations.

Preparations for pulmonary delivery. A levodopa-containing powder formulation for pulmonary delivery of levodopa has been developed through a process of micronization, along with a high-dose dry powder inhaler (Cyclops), for fast action and improving bioavailability in OFF periods of Parkinson disease (27). A randomized, double-blind, placebo-controlled, phase 3 trial showed that CVT-301 (Inbrija), a powder formation of levodopa for inhalation, can improve Unified Parkinson Disease Rating Scale motor scores of patients with Parkinson disease during OFF periods, with few severe or serious adverse events, but the long-term safety and efficacy need to be investigated in future studies (25). In December 2018, the U.S. Food and Drug Administration approved Inbrija for the intermittent treatment of OFF episodes in patients with Parkinson disease treated with carbidopa-levodopa. Although some pulmonary adverse events have been reported following inhalation of levodopa, these are mostly mild, and inhaled levodopa remains a useful rescue treatment of OFF episodes in Parkinson disease patients (46).

Pharmacogenetics. Response of motor symptoms of Parkinson disease is variable in individual patients, and different doses are required for control. Parkinson disease patients were genotyping for SV2C and SLC6A3 polymorphisms along with comedication, and demographic data for dosage prediction explain 23% of dose variation but needs to be validated by further studies (01).

Clinical trials

Levodopa was introduced in practice before clinical trials were required for drug approval. Several clinical trials have been conducted, and some of these are for new formulations of levodopa to improve delivery or for disorders other than Parkinson disease.

Interim results of a phase I study of levodopa-carbidopa intestinal gel delivered continuously via percutaneous endoscopic gastrojejunostomy tube showed that it was generally well tolerated and produced meaningful clinical improvements (14). A 12-week, randomized, controlled, double-blind clinical trial has tested continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson disease (36). Results showed that this method of delivery of levodopa is a promising option for control of advanced disease with motor complications, and benefits were of a greater magnitude than those obtained with other medical therapies thus far. A prospective, observational study included patients with advanced, levodopa-responsive Parkinson disease with either 2 to 4 hours of “off” time or 2 hours of dyskinesia daily showed significant and clinically relevant improvements in measures of activities of daily living, quality of life, and a specific subset of nonmotor symptoms such as sleep/fatigue after treatment with levodopa-carbidopa intestinal gel (22).

In a randomized, delayed-start, double-blind, placebo-controlled, multicenter trial of levodopa in patients with early-stage Parkinson disease (LEAP) who did not yet require medication were randomized to either 40 weeks of treatment with levodopa/carbidopa 100/25 mg TID, including 2 weeks of dose escalation, or to 40 weeks of placebo to determine possible disease-modifying effects of early levodopa therapy. Among patients with early Parkinson disease who were evaluated over the course of 80 weeks, treatment with levodopa-carbidopa 100/25 mg 3 times a day had no disease-modifying effect (52). The LEAP trial failed to confirm the hypothesis of levodopa as a potential disease-modifying intervention. Because of the heterogeneity of Parkinson disease, differences in underlying disease mechanisms, genotype, and other factors such as brain imaging and inflammatory biomarkers should be considered in future trials (05).

A phase 4 randomized trial was ongoing as of March 2019 to assess whether long-acting levodopa taken at bedtime improves obstructive sleep apnea in patients with Parkinson disease as compared with placebo (NCT03111485). The primary outcome will be the apnea-hypopnea index change from baseline to on-medication, comparing active medication to placebo. Other outcomes will include various polysomnographic parameters.

A 12-month, phase 3 safety and efficacy study of Inbrija (CVT-301), a levodopa inhalation powder, in Parkinson disease patients with OFF episodes met its primary endpoint, with patients showing a statistically significant improvement in motor function as measured by a reduction in Unified Parkinson Disease Rating Scale scores (NCT02242487).

Indications

Levodopa is indicated in the treatment of idiopathic Parkinson disease, postencephalitic parkinsonism, and parkinsonism that may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to have developed parkinsonism in association with cerebral arteriosclerosis.

Off-label uses

	(1) Dopa-responsive dystonia.
	(2) Rapid eye movement sleep behavior disorder preceding Parkinson disease.
	(3) According to a systematic review of controlled clinical trials, levodopa is effective for the short-term treatment of restless legs syndrome (45).
	(4) Narcolepsy.
	(5) As an adjunct therapy for the treatment of spastic quadriplegic cerebral palsy.
	(6) Levodopa, in combination with physiotherapy, has been used to enhance motor recovery in patients with chronic stroke.
	(7) Levodopa combined with behavioral contingency management is effective for treatment of cocaine dependence disorder (44).
	(8) Available evidence supports the traditional view that dysphagia of Parkinson disease is responsive to levodopa (50).
	(9) Parkinsonism developing after radiation and chemotherapy following surgery of malignant brain tumors in children is resistant to levodopa (29).
	(10) Results of a retrospective study show that levodopa improves central visual acuity in non-arteritic anterior ischemic optic neuropathy and may promote neuroprotection of the maculopapular retinal ganglion cell fibers (28).
	(11) A retrospective study has shown that age-related macular degeneration occurs significantly later in life in patients with a levodopa prescription as compared to those without a levodopa prescription (06). The protective effect of levodopa is plausible because GPR143, a G protein-coupled receptor that is exclusively expressed by melanocytes and retinal pigment epithelium, is the only known receptor for levodopa and is a promising target to combat age-related macular degeneration. A phase 2 clinical trial will assess the safety and tolerability of carbidopa-levodopa in patients with neovascular age-related macular degeneration who are already on treatment with anti-VEGF intraocular injections (NCT03023059).

Goals and duration of treatment

The levodopa challenge test (LCT) is a reliable assessment for diagnosis of de novo Parkinson disease and determining response to levodopa therapy. The patient receives a 250 mg dose of levodopa. Motor assessments at baseline using the motor portion (part III) of the Unified Parkinson Disease Rating Scale is done before and 1 hour after drug administration. The levodopa challenge test is an easy and generally safe procedure. The results of the test have significant implications in the management of patients, from preoperative evaluation for deep brain stimulation to providing guidance for medication adjustments for motor or nonmotor fluctuations and dyskinesias (42).

The goal of treatment is the control of parkinsonian symptoms, and treatment is continued on a long-term basis. Initially, levodopa is taken 3 or 4 times a day, and it reduces the signs and symptoms of the disease and may return the patient to full function. With continued treatment, fluctuations in motor response may appear, and the patient may notice a "wearing off" effect at the end of each dose cycle. Later, the response may become less predictable in relation to the dose, and dyskinesias may appear. The patient may go into an OFF-ON state, fluctuating between full functional recovery and complete disability. Negative response to levodopa and levodopa-induced dyskinesias accentuate fluctuations. Besides well-known motor and nonmotor symptoms of Parkinson disease, other manifestations can respond to levodopa therapy. One example is stridor due to bilateral vocal cord muscle dysfunction that may be related to nigrostriatal dopaminergic dysfunction in patients with Parkinson disease, and levodopa uptitration may be beneficial in relieving stridor and prevention of respiratory failure (51).

The issue of long-term effects of levodopa therapy, beneficial versus adverse, and the mechanism of these is not yet settled. No disease-modifying effect of levodopa has been demonstrated in the long-term follow-up of patients with Parkinson disease, although some studies have shown slowing of the disease progression.

Long-term levodopa/dopa decarboxylase inhibitor application with concomitant inhibition of both catechol-O-methyltransferase and monoamine oxidase-B supports a more continuous dopamine substitution, which ameliorates fluctuations of motor behavior (31).

The dose of levodopa should be tailored to the needs of an individual patient. Reduction of drug dose or drug discontinuation should be carried out if there are adverse effects of the drug.

Adverse effects

Levodopa infusion may improve some aspects of motor performance while worsening others. Different components of the motor cortico-striato-pallido-thalamo-cortical loop and related pathways may underlie motor improvement and adverse motor effects of levodopa therapy for Parkinson disease. Clinically, levodopa improves the symptoms of the disease and delays its progression. Although levodopa therapy may induce a decline in imaging measures of dopaminergic function as compared to placebo or dopamine agonists, indicating neurotoxic effects, a study of nigral neuronal count and Lewy body density in Parkinson disease showed that use of levodopa during lifetime does not enhance progression of Parkinson disease pathology (39). Neurologic complications are considered to be due to the nonphysiological replacement of dopamine. Various complications of levodopa therapy are discussed in the following paragraphs.

Movement disorders. The following types of movement disorders have been reported (18):

• Choreoathetosis. This is the most common.
• Dystonia. This occurs in 20% to 30% of patients.
• Akathisia. This occurs in 26% of patients, may precede treatment.
• Ballism. This can be severe.
• Stereotyped movements. This involves stepping or kicking movements of legs.
• Myoclonus. This is rare. It is usually in association with dementia.
• Tremor. Often present before treatment and difficult to evaluate.
• Dyskinesias. There are various types of dyskinesias associated with levodopa therapy. Peak dose or ON dyskinesia is the most frequent type. Diphasic dyskinesia occurs when levodopa begins to take effect, and as the drug effect wanes with minimal manifestations during the peak dose. In a prospective open-label study of Parkinson disease patients who suffered from peak-dose levodopa-induced dyskinesia, a pharmacokinetic/pharmacodynamic model following a single dose of levodopa equal to 150% of usual daily dose showed that the motor response and dyskinesia have close onsets and duration effects, with maximal motor response invariably associated with dyskinesia (47).

Continuous levodopa infusion with steady plasma levels of the drug is associated with reduced motor complications compared with the standard oral formulation of the drug that is associated with fluctuation of plasma levels, particularly low levels, in patients with advanced Parkinson disease. Continuous intraduodenal infusion of the levodopa/carbidopa enteral gel as monotherapy is safe and clinically superior to several individually optimized combinations of conventional oral and subcutaneous medications in patients with motor fluctuations. A retrospective, long-term follow-up analysis of the clinical experience with application of levodopa/carbidopa-gel suspension directly in the duodenum showed that a continuous delivery by a portable pump resulted in smoother plasma concentrations of levodopa, whereas the daily dose of levodopa decreased by 5% (34). Continuous jejunal levodopa infusion is an effective and feasible alternative treatment option for patients with advanced Parkinson disease, although there may be technical problems with the device (12).

Findings of PET studies suggest that dissociation between cerebral blood flow and cerebral metabolism is a distinctive feature of levodopa treatment and may be especially pronounced in patients with levodopa-induced dyskinesia (17).Chronic levodopa treatment leads to the development of microvascular changes such as angiogenesis, which can increase cerebral blood flow as well as enhance transport of the drug across the blood-brain barrier, but more research is needed to determine whether the degree of flow-metabolism dissociation seen in Parkinson disease patients is predictive of the subsequent development of levodopa-induced dyskinesias (20).

Peripheral side effects. These include nausea, vomiting, and postural hypotension.

Central side effects. These include visual hallucinations, psychoses, and disturbed sleep with vivid dreams. The rare complication of disordered respiration is described as a levodopa-induced dyskinesia, but irregular breathing patterns may be due to the effect of levodopa on the central control of respiration.

Levodopa withdrawal. A neuroleptic malignant-like syndrome (fever, akinetic crisis, rigidity, autonomic disturbances) has been reported following withdrawal of levodopa. This condition has been termed the parkinsonism hyperpyrexia syndrome. Withdrawal is more likely to precipitate a neuroleptic malignant-like syndrome when the patient is receiving concomitant neuroleptic therapy for psychiatric problems. Management includes replacing levodopa at the prior doses and aggressive supportive care in an intensive care unit.

Wearing-off. This is a complication of long-term levodopa therapy and is defined as re-emergence of symptoms of Parkinson disease before the next scheduled levodopa dose. It may require modification of the levodopa dose, switching to another levodopa formulation, and adjunct therapies, such as catechol-O-methyltransferase inhibitors and monoamine oxidase-B inhibitors (37).

Dopaminergic dysregulation syndrome. This syndrome can occur in patients with Parkinson disease due to long-term exposure to dopamine replacement therapy and is characterized by self-control problems such as addiction to medication, gambling, or sexual behavior. An experimental study in rats has shown that levodopa treatment restores the decreased spine density in spiny neurons in nucleus accumbens, which is caused by dopamine denervation, but can lead to the development of dyskinesia, and enlargement of the spine may be involved in dopaminergic dysregulation syndrome (15). A systematic review of literature revealed 98 cases of dopamine dysregulation syndrome that met substance use disorder criteria of DSM-5 (53). Past history showed substance disorder in 15.3% and psychiatric disorder in 10.2% of cases. Common comorbid conditions included impulse control disorders in 61%, psychosis in 32%, and panic attacks in 14%. Despite various management strategies, only 56% of cases were resolved. The authors of the study emphasized the importance of early detection of dopaminergic dysregulation disorder.

Progression of neurodegeneration in Parkinson disease. There is a suspicion that long-term use of levodopa may accelerate neurodegeneration in Parkinson disease. Levodopa can induce degeneration of dopaminergic neurons in cultures, but there is no conclusive evidence for neurotoxicity of levodopa in vivo. Deterioration in Parkinson disease patients may be due to natural progression of the disease and not due to levodopa. In the absence of prospective and properly controlled studies with unbiased counting, the issue of the neurotoxicity of levodopa has not been fully resolved and it is recommended that levodopa use should continue, but the lowest dose that provides clinical control of symptoms should be employed (35).

See also the Physicians’ Desk Reference.

Management of adverse effects. Levodopa-induced dyskinesias are problematic.

Levodopa-induced dyskinesias. To prevent peak dose dyskinesias, levodopa concentrations should be maintained in the therapeutic range, but below the dyskinesia threshold. According to the finding of an exploratory trial, levodopa in doses slowly titrated to 1000 mg/day could be useful in improving levodopa-induced dyskinesias (48). A metaanalysis of various studies has shown that adjuvant therapy such as dopamine agonists reduces off-time and levodopa dose and improves United Parkinson Disease Rating Scale scores in patients who develop motor complications on levodopa therapy, but this may be at the expense of increased dyskinesia and numerous other side effects (49). Safinamide, a monoamine oxidase-B inhibitor, blocks the enzyme that breaks down dopamine, thereby helping to restore dopamine levels in the brain and improving the patient's symptoms. In a double-blind, placebo-controlled study of Parkinson disease patients with motor fluctuations, safinamide increased ON time without increasing dyskinesia (04). It is approved in Europe as add-on therapy to a stable dose of levodopa alone or in combination with other therapies for mid-to late-stage Parkinson disease with fluctuations. Bilateral subthalamic nucleus deep brain stimulation attenuates levodopa-induced dyskinesia in patients with Parkinson disease without having to reduce the drug dosage (19).

Modified preparations of levodopa such as controlled release preparations and liquid levodopa, catecholamine-O-methyltransferase inhibitors, and dopamine agonists have been used in the prevention and treatment of motor complications.

A randomized, double-blind, placebo-controlled clinical trial has shown that extended release amantadine (ADS-5102), 274 mg at bedtime, may be an effective treatment for levodopa-induced dyskinesia (38). The FDA has approved an extended-release amantadine formulation that improved dyskinesia and OFF states in a once-daily evening dose in clinical trials, which provides higher as well as more continuous amantadine plasma bioavailability than conventional immediate-release formulations requiring 3 daily doses (32).

Serotonergic system and mGluR5 glutamate receptors are involved in complex molecular mechanisms that sustain levodopa-induced dyskinesias. Partial 5-HT1A/5-HT1B receptor agonist eltoprazine and mGluR5 negative allosteric modulator dipraglurant have shown encouraging results in phase 2 trials but large phase 3 trials are needed to confirm these results (08).

Deep brain stimulation of the subthalamic nucleus is effective in treating levodopa-induced dyskinesias (56). Repetitive transcranial magnetic stimulation over the cerebellum as continuous theta burst stimulation has an antidyskinetic effect in Parkinson disease patients with levodopa-induced dyskinesia (21). Strategies of continuous dopaminergic stimulation appear to be promising for preventing or ameliorating levodopa-induced dyskinesias (43).

Levodopa-induced psychoses. These may be treated with clozapine. If reduction of levodopa dose or alternative mode of delivery does not resolve neuropsychiatric symptoms, use of nondopaminergic agents and deep brain stimulation may enable control of symptoms of Parkinson disease with less risk of behavioral disorders (02).

Dopaminergic dysregulation syndrome. The first step in the management of dopaminergic dysregulation syndrome is levodopa dosage reduction, and symptoms may resolve. Some behavioral problems may respond to psychotherapy and social support. Antipsychotic drugs may be required in some cases with psychosis, aggression, compulsive gambling, or hypersexuality. Dopaminergic dysregulation syndrome has been treated successfully with valproic acid (13). Deep brain stimulation of the subthalamic region has been used for the treatment of dopaminergic treatment abuse in Parkinson disease (26).

References

01: Altmann V, Schumacher-Schuh AF, Rieck M, Callegari-Jacques SM, Rieder CR, Hutz MH. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease. Pharmacogenomics 2016;17(5):481-8. PMID 27019953
02: Beaulieu-Boire I, Lang AE. Behavioral effects of levodopa. Mov Disord 2015;30(1):90-102. PMID 25491470
03: Birkmayer W, Hornykiewicz O. Der L-Dioxyphenylalamin (=Dopa)-Effekt bei der Parkinson-akinase. Wien Klin Wschr 1961;73:787-8. PMID 13869404
04: Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord 2014;29(10):1273-80. PMID 25044402
05: Bressman S, Saunders-Pullman R. When to start levodopa therapy for Parkinson's disease. N Engl J Med 2019;380(4):389-90.** PMID 30673551
06: Brilliant MH, Vaziri K, Connor TB Jr, et al. Mining retrospective data for virtual prospective drug repurposing: L-DOPA and age-related macular degeneration. Am J Med 2016;129(3):292-8. PMID 26524704
07: Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959;11(2, Part 2):490-3. PMID 13667431
08: Cerri S, Siani F, Blandini F. Investigational drugs in phase i and phase ii for levodopa-induced dyskinesias. Expert Opin Investig Drugs 2017;26(7):777-91. PMID 28535734
09: Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol 2010;257(Suppl 2):S253-61. PMID 21080186
10: Cotzias GC. L-Dopa for parkinsonism. N Engl J Med 1968;278:630. PMID 5637779
11: Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology 2016;86(14 Suppl 1):S13-24. PMID 27044646
12: Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31(3):151-66. PMID 18520982
13: Epstein J, Madiedo CJ, Lai L, Hayes MT. Successful treatment of dopamine dysregulation syndrome with valproic acid. J Neuropsychiatry Clin Neurosci 2014 Summer;26(3):E3. PMID 25093777
14: Fernandez HH, Vanagunas A, Odin P, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord 2013;19(3):339-45. PMID 23287001
15: Funamizu Y, Nishijima H, Ueno T, et al. Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa. Neurosci Res 2017;121:49-53. PMID 28392304
16: Guggenheim M. Dioxyphenylalanin, eine neue aminosaüre aus Vicia faba. Z Physiol Chem 1913;88:276-84.
17: Hirano S, Asanuma K, Ma Y, et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci 2008;28(16):4201-9. PMID 18417699
18: Jain KK. Drug induced neurological disorders. 4th edition. Cham (Switzerland): Springer, 2021.
19: Kim JH, Chang WS, Jung HH, Chang JW. Effect of subthalamic deep brain stimulation on levodopa-induced dyskinesia in Parkinson's disease. Yonsei Med J 2015;56(5):1316-21. PMID 26256974
20: Ko JH, Lerner RP, Eidelberg D. Effects of levodopa on regional cerebral metabolism and blood flow. Mov Disord 2015;30(1):54-63. PMID 25296957
21: Koch G, Brusa L, Carrillo F, et al. Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease. Neurology 2009;73(2):113-9. PMID 19597133
22: Krüger R, Lingor P, Doskas T, et al. An observational study of the effect of levodopa-carbidopa intestinal gel on activities of daily living and quality of life in advanced Parkinson's disease patients. Adv Ther 2017;34(7):1741-52. PMID 28631218
23: LeWitt PA. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. Mov Disord 2015;30(1):64-72. PMID 25449210
24: LeWitt PA. New levodopa therapeutic strategies. Parkinsonism Relat Disord 2016;22 Suppl 1:S37-40. PMID 26459662
25: LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019;18(2):145-54.** PMID 30663606
26: Lhommée E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012;135(Pt 5):1463-77. PMID 22508959
27: Luinstra M, Grasmeijer F, Hagedoorn P, Moes JR, Frijlink HW, de Boer AH. A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods. Eur J Pharm Biopharm 2015;97(Pt A):22-9. PMID 26453913
28: Lyttle DP, Johnson LN, Margolin EA, Madsen RW. Levodopa as a possible treatment of visual loss in nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2016;254(4):757-64.** PMID 26483145
29: Mehanna R, Jimenez-Shahed J, Itin I. Three cases of levodopa-resistant parkinsonism after radiation therapy. Am J Case Rep 2016;17:916-20. PMID 27909286
30: Mittur A, Gupta S, Modi NB. Pharmacokinetics of Rytary®, an extended-release capsule formulation of carbidopa-levodopa. Clin Pharmacokinet 2017;56(9):999-1014. PMID 28236251
31: Müller T. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease. Expert Opin Drug Metab Toxicol 2020;16(5):403-14.** PMID 32238065
32: Müller T, Möhr JD. Recent clinical advances in pharmacotherapy for levodopa-induced dyskinesia. Drugs 2019;79(13):1367-74. PMID 31332769
33: Ngwuluka N, Pillay V, Du Toit LC, et al. Levodopa delivery systems: advancements in delivery of the gold standard. Expert Opin Drug Deliv 2010;7(2):203-24. PMID 20095943
34: Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci 2008;29 Suppl 5:S387-8. PMID 19381770
35: Olanow CW. Levodopa: effect on cell death and the natural history of Parkinson's disease. Mov Disord 2015;30(1):37-44. PMID 25502620
36: Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13(2):141-9. PMID 24361112
37: Pahwa R, Lyons KE. Levodopa-related wearing-off in Parkinson's disease: identification and management. Curr Med Res Opin 2009;25(4):841-9. PMID 19228103
38: Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol 2017;74(8):941-9.** PMID 28604926
39: Parkkinen L, O'Sullivan SS, Kuoppamäki M, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain. Neurology 2011;77(15):1420-6. PMID 21917769
40: Pezzoli G, Zini M. Levodopa in Parkinson's disease: from the past to the future. Expert Opin Pharmacother 2010;11(4):627-35. PMID 20163273
41: Pilleri M, Antonini A. Novel levodopa formulations in the treatment of Parkinson's disease. Expert Rev Neurother 2014;14(2):143-9. PMID 24428803
42: Saranza G, Lang AE. Levodopa challenge test: indications, protocol, and guide. J Neurol 2020. [Epub ahead of print.] ** PMID 32333167
43: Schaeffer E, Pilotto A, Berg D. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease. CNS Drugs 2014;28(12):1155-84. PMID 25342080
44: Schmitz JM, Lindsay JA, Stotts AL, Green CE, Moeller FG. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. Exp Clin Psychopharmacol 2010;18(3):238-44. PMID 20545388
45: Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Levodopa for restless legs syndrome. Cochrane Database Syst Rev 2011;(2):CD005504. PMID 21328278
46: Simões RM, Castro Caldas A, Ferreira JJ. Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease. Expert Rev Clin Pharmacol 2020;13(2):85-101.** PMID 32011195
47: Simon N, Viallet F, Boulamery A, Eusebio A, Gayraud D, Azulay JP. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. Eur J Clin Pharmacol 2016;72(4):423-30. PMID 26936272
48: Stathis P, Konitsiotis S, Tagaris G, Peterson D; VALID-PD Study Group. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2011;26(2):264-70. PMID 21412833
49: Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev 2010;(7):CD007166. PMID 20614454
50: Sutton JP. Dysphagia in Parkinson's disease is responsive to levodopa. Parkinsonism Relat Disord 2013;19(3):282-4. PMID 23333537
51: Tsai CC, Wu MN, Liou LM, Chang YP. Levodopa reverse stridor and prevent subsequent endotracheal intubation in Parkinson disease patients with bilateral vocal cord palsy: a case report. Medicine (Baltimore) 2016;95(50):e5559.** PMID 27977587
52: Verschuur CV, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of levodopa in Parkinson's disease. N Engl J Med 2019;380(4):315-24. PMID 30673543
53: Warren N, O'Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson's disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry 2017;88(12):1060-4. PMID 29018160
54: Westin J, Nyholm D, Pålhagen S, et al. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. Clin Neuropharmacol 2011;34(2):61-5. PMID 21297456
55: Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson's disease: a systematic review. CNS Drugs 2016;30(5):381-404. PMID 27138916
56: Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. Curr Neurol Neurosci Rep 2007;7(4):302-10. PMID 17618536

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Levodopa

Other Pertinent Drugs

Benserazide (peripheral decarboxylase inhibitor) combined with levodopa
Carbidopa (a decarboxylase inhibitor) combined with levodopa

Also Relevant

Dementia in Parkinson disease
Dopa-responsive dystonia
Narcolepsy
Neuropharmacology
Parkinson disease
- Restless legs syndrome

Levodopa …

Levodopa

Introduction

Overview

Key points

Historical note and terminology

Pharmacology

Clinical trials

Indications

Off-label uses

Contraindications

Goals and duration of treatment

Dosing

Special considerations

Interactions

Adverse effects

References

Contributors

Author

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Drug-induced myasthenic syndromes

Acupuncture

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Levodopa

Introduction

Overview

Key points

Historical note and terminology

Pharmacology

Clinical trials

Indications

Off-label uses

Contraindications

Goals and duration of treatment

Dosing

Special considerations

Interactions

Adverse effects

References

Contributors

Author

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Drug-induced myasthenic syndromes

Acupuncture

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

This is an article preview.
Start a Free Account
to access the full version.